I was just reading through the latest Bell Potter Research:
"special voucher allows the owner to have any of its investigational drugs reviewed under the FDA’s priority review pathway i.e. FDA will be obligated to review the drug within 6 months instead of the standard 10 months. MSB can decide to either use this voucher to accelerate the path to market of any of its other pipeline drugs or sell it to another company for multi-million dollars. Three companies have sold their rare disease priority review vouchers for multimillion dollars ranging from US$67.5m to US$350m."
I do note United Therapeutics sold its priority review voucher for $350m to AbbVie this year. What's the chance of us using it or selling it?
I was just reading through the latest Bell Potter Research:...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.020(1.78%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.13 | $1.09 | $4.556M | 4.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9590 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 3132 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |